The Immune Microenvironment in Mesothelioma: Mechanisms of Resistance to Immunotherapy

Although mesothelioma is the consequence of a protracted immune response to asbestos fibers and characterized by a clear immune infiltrate, novel immunotherapy approaches show less convincing results as compared to those seen in melanoma and non-small cell lung cancer. The immune suppressive microenvironment in mesothelioma is likely contributing to this therapy resistance. Therefore, it is important to explore the characteristics of the tumor microenvironment for explanations for this recalcitrant behavior. This review describes the stromal, cytokine, metabolic, and cellular milieu of mesothelioma, and attempts to make connection with the outcome of immunotherapy trials.

[1]  M. Maio,et al.  NK‐ and T‐cell subsets in malignant mesothelioma patients: Baseline pattern and changes in the context of anti‐CTLA‐4 therapy , 2019, International journal of cancer.

[2]  R. Stahel,et al.  A multicentre randomized phase III trial comparing pembrolizumab (P) vs single agent chemotherapy (CT) for advanced pre-treated malignant pleural mesothelioma (MPM): Results from the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial , 2019, Annals of Oncology.

[3]  G. Scagliotti,et al.  Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): a double-blind, randomised, placebo-controlled phase 3 trial. , 2019, The Lancet. Respiratory medicine.

[4]  David R. Jones,et al.  Abstract CT036: A phase I clinical trial of malignant pleural disease treated with regionally delivered autologous mesothelin-targeted CAR T cells: Safety and efficacy , 2019, Clinical Trials.

[5]  M. Zauderer,et al.  A phase Ib study of GSK3052230, an FGF ligand trap in combination with pemetrexed and cisplatin in patients with malignant pleural mesothelioma , 2019, Investigational New Drugs.

[6]  Larissa V Furtado,et al.  Tumor PD-L1 expression in malignant pleural and peritoneal mesothelioma by Dako PD-L1 22C3 pharmDx and Dako PD-L1 28-8 pharmDx assays. , 2019, Human pathology.

[7]  S. Pastorino,et al.  Targeting the C-terminus of galectin-9 induces mesothelioma apoptosis and M2 macrophage depletion , 2019, Oncoimmunology.

[8]  J. Zucman‐Rossi,et al.  Dissecting heterogeneity in malignant pleural mesothelioma through histo-molecular gradients for clinical applications , 2019, Nature Communications.

[9]  Sarah H. Johnson,et al.  Neoantigenic Potential of Complex Chromosomal Rearrangements in Mesothelioma , 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[10]  S. Lantuejoul,et al.  Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial. , 2019, The Lancet. Oncology.

[11]  M. Sadelain,et al.  Calibration of CAR activation potential directs alternative T cell fates and therapeutic potency , 2018, Nature Medicine.

[12]  S. M. Toor,et al.  Immune checkpoint inhibitors: recent progress and potential biomarkers , 2018, Experimental & Molecular Medicine.

[13]  N. Matsumura,et al.  VISTA expressed in tumour cells regulates T cell function , 2018, British Journal of Cancer.

[14]  N. Pavlakis,et al.  Pembrolizumab as Palliative Immunotherapy in Malignant Pleural Mesothelioma , 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[15]  T. Negri,et al.  Complex Immune Contextures Characterise Malignant Peritoneal Mesothelioma: Loss of Adaptive Immunological Signature in the More Aggressive Histological Types , 2018, Journal of immunology research.

[16]  E. Song,et al.  Turning foes to friends: targeting cancer-associated fibroblasts , 2018, Nature Reviews Drug Discovery.

[17]  Bin Zhao,et al.  Efficacy of PD-1 or PD-L1 inhibitors and PD-L1 expression status in cancer: meta-analysis , 2018, British Medical Journal.

[18]  E. Morii,et al.  Origin of cancer-associated fibroblasts and tumor-associated macrophages in humans after sex-mismatched bone marrow transplantation , 2018, Communications Biology.

[19]  Yongbaek Kim,et al.  Hypoxia promotes acquisition of aggressive phenotypes in human malignant mesothelioma , 2018, BMC cancer.

[20]  M. Rönty,et al.  Pirfenidone decreases mesothelioma cell proliferation and migration via inhibition of ERK and AKT and regulates mesothelioma tumor microenvironment in vivo , 2018, Scientific Reports.

[21]  T. Seiwert,et al.  Phase II trial of pembrolizumab (P) in patients (pts) with previously-treated mesothelioma (MM). , 2018 .

[22]  V. Gorgoulis,et al.  Targeting Tie-2/angiopoietin axis in experimental mesothelioma confers differential responses and raises predictive implications , 2018, Oncotarget.

[23]  S. Moriyama,et al.  Four immunohistochemical assays to measure the PD-L1 expression in malignant pleural mesothelioma , 2018, Oncotarget.

[24]  S. Steinberg,et al.  Tumor-Derived GM-CSF Promotes Granulocyte Immunosuppression in Mesothelioma Patients , 2018, Clinical Cancer Research.

[25]  D. Noonan,et al.  Natural Killer Cells from Malignant Pleural Effusion Are Endowed with a Decidual-Like Proangiogenic Polarization , 2018, Journal of immunology research.

[26]  H. Rehrauer,et al.  How asbestos drives the tissue towards tumors: YAP activation, macrophage and mesothelial precursor recruitment, RNA editing, and somatic mutations , 2017, bioRxiv.

[27]  N. Maskell,et al.  Introducing the new BTS guideline: the investigation and management of pleural malignant mesothelioma , 2018, Thorax.

[28]  J. Rathmell,et al.  Metabolic Barriers to T Cell Function in Tumors , 2018, The Journal of Immunology.

[29]  E. Felley-Bosco,et al.  The “don't eat me” signal CD47 is a novel diagnostic biomarker and potential therapeutic target for diffuse malignant mesothelioma , 2017, Oncoimmunology.

[30]  N. Hens,et al.  Abundant expression of TIM-3, LAG-3, PD-1 and PD-L1 as immunotherapy checkpoint targets in effusions of mesothelioma patients , 2017, Oncotarget.

[31]  K. Nackaerts,et al.  Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial. , 2017, The Lancet. Oncology.

[32]  G. Thomas,et al.  Evaluating the effect of immune cells on the outcome of patients with mesothelioma , 2017, British Journal of Cancer.

[33]  A. Santoro,et al.  Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial. , 2017, The Lancet. Oncology.

[34]  J. Champion,et al.  Quantitative analysis of the role of fiber length on phagocytosis and inflammatory response by alveolar macrophages. , 2017, Biochimica et biophysica acta. General subjects.

[35]  Yusuke Nakamura,et al.  Integrated analysis of somatic mutations and immune microenvironment in malignant pleural mesothelioma , 2017, Oncoimmunology.

[36]  N. Hens,et al.  Prognostic and predictive aspects of the tumor immune microenvironment and immune checkpoints in malignant pleural mesothelioma , 2017, Oncoimmunology.

[37]  P. Jänne,et al.  Cytotoxic T Cells in PD-L1–Positive Malignant Pleural Mesotheliomas Are Counterbalanced by Distinct Immunosuppressive Factors , 2016, Cancer Immunology Research.

[38]  C. Blanquart,et al.  Pleural Effusions from Patients with Mesothelioma Induce Recruitment of Monocytes and Their Differentiation into M2 Macrophages , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[39]  J. Aerts,et al.  Pleural Effusion of Patients with Malignant Mesothelioma Induces Macrophage‐Mediated T Cell Suppression , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[40]  R. Salgia,et al.  PI3 Kinase Pathway and MET Inhibition is Efficacious in Malignant Pleural Mesothelioma , 2016, Scientific Reports.

[41]  A. Mansfield,et al.  c-Met expression and MET amplification in malignant pleural mesothelioma. , 2016, Annals of diagnostic pathology.

[42]  Yang Feng,et al.  Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition. , 2016, The Journal of clinical investigation.

[43]  Peter J. Murray,et al.  Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards , 2016, Nature Communications.

[44]  B. Turlach,et al.  Longitudinal Measurement of Pleural Fluid Biochemistry and Cytokines in Malignant Pleural Effusions. , 2016, Chest.

[45]  A. C. Tanrıkulu,et al.  Prognostic value of the lymphocyte-to-monocyte ratio and other inflammatory markers in malignant pleural mesothelioma , 2016, Environmental Health and Preventive Medicine.

[46]  Olivier Molinier,et al.  Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial , 2016, The Lancet.

[47]  C. June,et al.  A Chimeric Switch-Receptor Targeting PD1 Augments the Efficacy of Second-Generation CAR T Cells in Advanced Solid Tumors. , 2016, Cancer research.

[48]  S. Albelda,et al.  Asbestos Induces Oxidative Stress and Activation of Nrf2 Signaling in Murine Macrophages: Chemopreventive Role of the Synthetic Lignan Secoisolariciresinol Diglucoside (LGM2605) , 2016, International journal of molecular sciences.

[49]  Thomas D. Wu,et al.  Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations , 2016, Nature Genetics.

[50]  S. Yano,et al.  Fibrocyte-like cells mediate acquired resistance to anti-angiogenic therapy with bevacizumab , 2015, Nature Communications.

[51]  Y. C. Lee,et al.  Characterization of hypoxia in malignant pleural mesothelioma with FMISO PET-CT. , 2015, Lung cancer.

[52]  R. Hubbard,et al.  Demographics, management and survival of patients with malignant pleural mesothelioma in the National Lung Cancer Audit in England and Wales. , 2015, Lung cancer.

[53]  David R. Jones,et al.  The tumoral and stromal immune microenvironment in malignant pleural mesothelioma: A comprehensive analysis reveals prognostic immune markers , 2015, Oncoimmunology.

[54]  E. Felip,et al.  Analysis of Expression of Programmed Cell Death 1 Ligand 1 (PD-L1) in Malignant Pleural Mesothelioma (MPM) , 2015, PloS one.

[55]  E. Gazzano,et al.  Zoledronic acid overcomes chemoresistance and immunosuppression of malignant mesothelioma , 2014, Oncotarget.

[56]  E. Cotte,et al.  Erratum to: Malignant Peritoneal Mesothelioma Treated by Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: Is GLUT1 Expression a Major Prognostic Factor? A Preliminary Study , 2014, Annals of Surgical Oncology.

[57]  M. Sadelain,et al.  Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity , 2014, Science Translational Medicine.

[58]  B. Ghanim,et al.  Fibroblast growth factor receptor inhibition is active against mesothelioma and synergizes with radio- and chemotherapy. , 2014, American journal of respiratory and critical care medicine.

[59]  H. Hoogsteden,et al.  Ratio of Intratumoral Macrophage Phenotypes Is a Prognostic Factor in Epithelioid Malignant Pleural Mesothelioma , 2014, PloS one.

[60]  M. Bovenzi,et al.  Increased Levels of C-C Chemokine RANTES in Asbestos Exposed Workers and in Malignant Mesothelioma Patients from an Hyperendemic Area , 2014, PloS one.

[61]  P. Dessen,et al.  PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced MDSC-mediated T cell activation , 2014, The Journal of experimental medicine.

[62]  C Goparaju,et al.  Autocrine CSF-1R signaling drives mesothelioma chemoresistance via AKT activation , 2014, Cell Death and Disease.

[63]  R. Stahel,et al.  Treatment of malignant pleural mesothelioma by fibroblast activation protein-specific re-directed T cells , 2013, Journal of Translational Medicine.

[64]  M. Noppen,et al.  Defect in recruiting effector memory CD8+ T-cells in malignant pleural effusions compared to normal pleural fluid , 2013, BMC Cancer.

[65]  E. Cotte,et al.  Malignant Peritoneal Mesothelioma Treated by Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: Is GLUT1 Expression a Major Prognostic Factor? A Preliminary Study , 2013, Annals of Surgical Oncology.

[66]  G. Passalacqua,et al.  NK cells from malignant pleural effusions are not anergic but produce cytokines and display strong antitumor activity on short‐term IL‐2 activation , 2013, European journal of immunology.

[67]  B. Robinson,et al.  IL-2/CD40-driven NK cells install and maintain potency in the anti-mesothelioma effector/memory phase. , 2012, International immunology.

[68]  E. Vokes,et al.  Vatalanib in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (CALGB 30107). , 2012, Lung cancer.

[69]  A. Scherpereel,et al.  CCL2, Galectin-3, and SMRP Combination Improves the Diagnosis of Mesothelioma in Pleural Effusions , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[70]  Hidemi Ito,et al.  TGF-β synergizes with defects in the Hippo pathway to stimulate human malignant mesothelioma growth , 2012, The Journal of experimental medicine.

[71]  T. Nakajima,et al.  L-type amino acid transporter 1 (LAT1) expression in malignant pleural mesothelioma. , 2011, Anticancer research.

[72]  B. Levine,et al.  The PDL1-PD1 Axis Converts Human TH1 Cells into Regulatory T Cells , 2011, Science Translational Medicine.

[73]  D. Sugarbaker,et al.  Circulating and tumor‐infiltrating myeloid cells predict survival in human pleural mesothelioma , 2011, Cancer.

[74]  G. Coukos,et al.  The parallel lives of angiogenesis and immunosuppression: cancer and other tales , 2011, Nature Reviews Immunology.

[75]  Wei Wang,et al.  Tumorigenesis and Neoplastic Progression Pleural Mesothelioma Instigates Tumor-Associated Fibroblasts To Promote Progression via a Malignant Cytokine Network , 2011 .

[76]  Lin Zhang,et al.  Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and Treg cells , 2011, Nature.

[77]  Jing Sun,et al.  Expression of a Functional CCR2 Receptor Enhances Tumor Localization and Tumor Eradication by Retargeted Human T cells Expressing a Mesothelin-Specific Chimeric Antibody Receptor , 2011, Clinical Cancer Research.

[78]  A. Scherpereel,et al.  Identification of novel markers for the diagnosis of malignant pleural mesothelioma. , 2011, The American journal of pathology.

[79]  L. You,et al.  The expression of CXCR4, CXCL12 and CXCR7 in malignant pleural mesothelioma , 2011, The Journal of pathology.

[80]  T. Padhya,et al.  HIF-1α regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment , 2010, The Journal of experimental medicine.

[81]  N. Pavlakis,et al.  High Blood Neutrophil-to-Lymphocyte Ratio Is an Indicator of Poor Prognosis in Malignant Mesothelioma Patients Undergoing Systemic Therapy , 2010, Clinical Cancer Research.

[82]  L. Coussens,et al.  Macrophage expression of hypoxia-inducible factor-1 alpha suppresses T-cell function and promotes tumor progression. , 2010, Cancer research.

[83]  H. Pass,et al.  Programmed necrosis induced by asbestos in human mesothelial cells causes high-mobility group box 1 protein release and resultant inflammation , 2010, Proceedings of the National Academy of Sciences.

[84]  M. Nishimura,et al.  CD8+ tumor-infiltrating lymphocytes predict favorable prognosis in malignant pleural mesothelioma after resection , 2010, Cancer Immunology, Immunotherapy.

[85]  A. Chella,et al.  Multimodality treatment of malignant pleural mesothelioma with or without immunotherapy: does it change anything? , 2010, Interactive cardiovascular and thoracic surgery.

[86]  Craig A. Poland,et al.  Asbestos, carbon nanotubes and the pleural mesothelium: a review of the hypothesis regarding the role of long fibre retention in the parietal pleura, inflammation and mesothelioma , 2010, Particle and Fibre Toxicology.

[87]  Alfonso Baldi,et al.  Global Gene Expression Profiling Of Human Pleural Mesotheliomas: Identification of Matrix Metalloproteinase 14 (MMP-14) as Potential Tumour Target , 2009, PloS one.

[88]  S. Bielsa,et al.  Clinical impact and reliability of pleural fluid mesothelin in undiagnosed pleural effusions. , 2009, American journal of respiratory and critical care medicine.

[89]  G. Alí,et al.  Tryptase Mast Cells in Malignant Pleural Mesothelioma as an Independent Favorable Prognostic Factor , 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[90]  S. Cornwall,et al.  Local effector failure in mesothelioma is not mediated by CD4+ CD25+ T-regulator cells , 2009, European Respiratory Journal.

[91]  Craig Murdoch,et al.  The role of myeloid cells in the promotion of tumour angiogenesis , 2008, Nature Reviews Cancer.

[92]  M. Tsao,et al.  Impact of tumor-infiltrating T cells on survival in patients with malignant pleural mesothelioma. , 2008, The Journal of thoracic and cardiovascular surgery.

[93]  Zhijin Wu,et al.  Targeting tumor-associated macrophages in an orthotopic murine model of diffuse malignant mesothelioma , 2008, Molecular Cancer Therapeutics.

[94]  Richard P. Hill,et al.  Hypoxia and metabolism: Hypoxia, DNA repair and genetic instability , 2008, Nature Reviews Cancer.

[95]  F. Schmidt.  Meta-Analysis , 2008 .

[96]  F. Galateau-Sallé,et al.  EGFR and PDGFR differentially promote growth in malignant epithelioid mesothelioma of short and long term survivors , 2007, Thorax.

[97]  K. Gupta,et al.  Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer , 2007, Nature Medicine.

[98]  A. Berner,et al.  Chemokine receptors are infrequently expressed in malignant and benign mesothelial cells. , 2007, American journal of clinical pathology.

[99]  H. Pass,et al.  TNF-α inhibits asbestos-induced cytotoxicity via a NF-κB-dependent pathway, a possible mechanism for asbestos-induced oncogenesis , 2006, Proceedings of the National Academy of Sciences.

[100]  H. Hammad,et al.  Mesothelioma environment comprises cytokines and T-regulatory cells that suppress immune responses , 2006, European Respiratory Journal.

[101]  Jing Xian Lee,et al.  Intra-tumoural regulatory T cells: a potential new target in cancer immunotherapy. , 2006, Biochemical and biophysical research communications.

[102]  David J Sugarbaker,et al.  Tumorigenesis and Neoplastic Progression Identification of Novel Candidate Oncogenes and Tumor Suppressors in Malignant Pleural Mesothelioma Using Large-Scale Transcriptional Profiling , 2005 .

[103]  C. June,et al.  Regulatory T cells and cytokines in malignant pleural effusions secondary to mesothelioma and carcinoma , 2005, Cancer biology & therapy.

[104]  K. O'Byrne,et al.  Matrix metalloproteinases 2 and 9 (gelatinases A and B) expression in malignant mesothelioma and benign pleura , 2003, British Journal of Cancer.

[105]  Z. Liu,et al.  Regulation of matrix metalloprotease activity in malignant mesothelioma cell lines by growth factors , 2003, Thorax.

[106]  K. Krejcy,et al.  Chemotherapy for malignant pleural mesothelioma: past results and recent developments , 2003, British Journal of Cancer.

[107]  K. O'Byrne,et al.  Cyclooxygenase-2 expression is a novel prognostic factor in malignant mesothelioma. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[108]  K. O'Byrne,et al.  Angiogenesis is an independent prognostic factor in malignant mesothelioma , 2001, British Journal of Cancer.

[109]  O. Finn,et al.  Activated granulocytes and granulocyte-derived hydrogen peroxide are the underlying mechanism of suppression of t-cell function in advanced cancer patients. , 2001, Cancer research.

[110]  Shogo Tanaka, Nonghoon Choe, Akigawa Iwagaki, Davi.  ASBESTOS EXPOSURE INDUCES MCP-1 SECRETION BY PLEURAL MESOTHELIAL CELLS , 2000 .

[111]  E. van Marck,et al.  Angiogenic cytokines in mesothelioma: a study of VEGF, FGF‐1 and ‐2, and TGF β expression , 1999, The Journal of pathology.

[112]  J. Y. Liu,et al.  TNF-alpha receptor knockout mice are protected from the fibroproliferative effects of inhaled asbestos fibers. , 1998, The American journal of pathology.

[113]  B. Robinson,et al.  Sera from patients with malignant mesothelioma can contain autoantibodies. , 1998, Lung cancer.

[114]  B. Baskin,et al.  Hepatocyte growth factor/scatter factor stimulates chemotaxis and growth of malignant mesothelioma cells through c‐met receptor , 1998, International journal of cancer.

[115]  S. H. Park,et al.  Participation of iron and nitric oxide in the mutagenicity of asbestos in hgprt-, gpt+ Chinese hamster V79 cells. , 1998, Cancer research.

[116]  J. Klominek,et al.  Differential motile response of human malignant mesothelioma cells to fibronectin, laminin and collagen type IV: The role of β1 integrins , 1997, International journal of cancer.

[117]  V L Roggli,et al.  Pleural macrophage recruitment and activation in asbestos-induced pleural injury. , 1997, Environmental health perspectives.

[118]  C. Chao,et al.  Participation of nitric oxide and iron in the oxidation of DNA in asbestos-treated human lung epithelial cells. , 1996, Archives of biochemistry and biophysics.

[119]  S. Weitzman,et al.  Asbestos causes DNA strand breaks in cultured pulmonary epithelial cells: role of iron-catalyzed free radicals. , 1995, The American journal of physiology.

[120]  T. Hada,et al.  Transforming growth factor‐beta 1 (TGF‐β1)‐ and β2‐like activities in malignant pleural effusions caused by malignant mesothelioma or primary lung cancer , 1994 .

[121]  K. Sundqvist,et al.  Chemotaxis and haptotaxis of human malignant mesothelioma cells: effects of fibronectin, laminin, type IV collagen, and an autocrine motility factor-like substance. , 1993, Cancer research.

[122]  T. Hei,et al.  Chrysotile fiber is a strong mutagen in mammalian cells. , 1992, Cancer research.

[123]  P. Hegde,et al.  Molecular and Histopathological Characterization of the Tumor Immune Microenvironment in Advanced Stage of Malignant Pleural Mesothelioma , 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[124]  A. Gown,et al.  Guidelines for Pathologic Diagnosis of Malignant Mesothelioma 2017 Update of the Consensus Statement From the International Mesothelioma Interest Group. , 2018, Archives of pathology & laboratory medicine.

[125]  M. Millward,et al.  P2.06-026 A Phase II Trial of the Oral FGF Receptor Inhibitor AZD4547 as 2nd or 3rd Line Therapy in Malignant Pleural Mesothelioma - Trial in Progress: Topic: Mesothelioma and SCLC , 2017 .

[126]  C. June,et al.  Distinct Signaling of Coreceptors Regulates Specific Metabolism Pathways and Impacts Memory Development in CAR T Cells. , 2016, Immunity.

[127]  M. Oda,et al.  Comparative immunohistochemical analysis of IMP3, GLUT1, EMA, CD146, and desmin for distinguishing malignant mesothelioma from reactive mesothelial cells. , 2014, American journal of clinical pathology.

[128]  C. Palumbo,et al.  Differential effects of malignant mesothelioma cells on THP-1 monocytes and macrophages. , 2009, International journal of oncology.

[129]  D. Fennell,et al.  Expression and prognostic significance of hypoxia-inducible factor 1α (HIF-1α) in malignant pleural mesothelioma (MPM) , 2006 .